HMGCR and neoplasm: The involvement of the HMGCR-mediated mevalonate pathway in the anti-tumor immune responses has been implicated by previous research, which demonstrated increased immune responses to tumor cells undergoing vaccine adjuvants and cancer immunotherapies following interruption of the mevalonate pathway55.